BioStock: Coegin Pharma receives final approval for COAK Study
After complying with the conditions given by the Danish Ethics committee in September, Nordic biotech Coegin Pharma has received the final approval for initiating the phase I/II COAK study in actinic keratosis patients. From the beginning of November, the company will begin patient recruitment, and thus take an important step towards developing a novel treatment for a disease with a large unmet medical need.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/
InDex Pharmaceuticals updates the timeline of the phase III study CONCLUDE with cobitolimod
January 27, 2023 – InDex Pharmaceuticals Holding AB (publ) today announced an update in the timing of the dose selection in the ongoing phase III study CONCLUDE with the drug candidate cobitolimod. The outcome of the dose selection is expected to be available Q4 2023. At that point in time InDex wil...
InDex Pharmaceuticals uppdaterar tidplanen för fas III-studien CONCLUDE med cobitolimod
27 januari, 2023 – InDex Pharmaceuticals Holding AB (publ) meddelar idag en uppdatering av tidplanen för valet av dos i den pågående fas III-studien CONCLUDE med läkemedelskandidaten cobitolimod. Utfallet av dosvalet förväntas fjärde kvartalet 2023. Vid den tidpunkten har InDex slutfört bedömning av...
Mentice’s CEO Göran Malmberg to present the company’s Year-end Report Q4 2022 at a earnings call on February 3rd at 10:00 CET
The presentation of the Year-end Report Q4 for the period October – December 2022 will be held on February 3rd, 2023, at 10:00 CET. The live broadcast is followed by a Q&A moderated by Redeye’s analyst Christian Binder. For more information on how to register, please visit https://investor.menti...